View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Nuveen New Jersey Quality Muni Income Fd and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 11 November 2024 in which we reassessed the appropriateness of the...

Opko Health Inc: 1 director

A director at Opko Health Inc bought 280,183 shares at 1.505USD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: November 9, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: November 8, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: November 7, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

OPKO Health Reports Third Quarter 2024 Business Highlights and Financi...

OPKO Health Reports Third Quarter 2024 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, Nov. 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and nine months ended September 30, 2024. Highlights from the third quarter of 2024 and recent weeks include the following: Completed sale of select assets of BioReference Health to Labcorp for $237.5 million. OPKO completed the sale of BioReference Health’s laboratory testing businesses focused on clinical diagn...

 PRESS RELEASE

OPKO Health to Report Third Quarter 2024 Financial Results on November...

OPKO Health to Report Third Quarter 2024 Financial Results on November 7, 2024 MIAMI, Oct. 29, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended September 30, 2024 after the close of the U.S. financial markets on Thursday, November 7, 2024. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on November 7th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: October 19, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

FedEx Corporation - August 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: October 12, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

LUV SOUTHWEST AIRLINES CO
TTSH TILE SHOP HOLDINGS INC.
MOFG MIDWESTONE FINANCIAL GROUP
MEI METHODE ELECTRONICS INC.
KVHI KVH INDUSTRIES INC.
GDOT GREEN DOT CORPORATION CLASS A
CTRN CITI TRENDS INC.
CRMT AMERICA'S CAR-MART INC.
CODI COMPASS DIVERSIFIED HOLDINGS
CDXS CODEXIS
AHH ARMADA HOFFLER PROPERTIES INC.
NEWT NEWTEK BUSINESS SERVICES INC.
A0JMXQ INDIA CAPITAL GROWTH FUND LTD.
RLMD RELMADA THERAPEUTICS
CULP CULP INC.
EBF ENNIS
APTV APTIV PLC
NANX NANOPHASE TECHNOLOGIES CORP.
AXR AMREP
ETON ETON PHARMACEUTICALS
STIM STIMSONITE CORP
INMB INMUNE BIO
NFE INC.
CAPR NEW FORTRESS ENERGY
EPSN CAPRICOR THERAPEUTICS
FBIO EPSILON ENERGY LIMITED
WSC FABIEN CORP
VRDN WILLSCOT MOBILE MINI HOLDINGS CORP
CTLP VIRIDIAN THERAPEUTICS INC
SMMT CANTALOUPE
PFBX INC.
BMEA SUMMIT THERAPEUTICS INC
FTHY PEOPLES FINANCIAL CORP. (MISSISSIPPI)
ASLE BIOMEA FUSION
BHVN INC.
BIGZ FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND
BUKS AERSALE CORP
ECBK BIOHAVEN LTD
CDIO BLACKROCK INNOVATION AND GROWTH TST
GRNT BUTLER NATIONAL CORP
GTE ECB BANCORP INC.
CRBP CARDIO DIAGNOSTICS HLDGS INC
BMEZ GRANITE RIDGE RESOURCES INC
ASGI GRAN TIERRA ENERGY INC.
SYRS CORBUS PHARMACEUTICALS HOLDINGS INC.
PEO BLACKROCK HEALTH SCIENCES TERM TRUST
XPER ABERDEEN STANDARD GLOBAL INFRASTRUCTURE INCOME FUND
OMIC SYROS PHARMACEUTICALS INC.
PMN PETROLEUM & RESOURCES CORPORATION
BNTC XPERI INC
CLNN SINGULAR GENOMICS SYSTEMS INC
BNZI PROMIS NEUROSCIENCES INC.
SIRI BENITEC BIOPHARMA INC
CLENE INC
BANZAI INTERNATIONAL INC
SIRIUS XM HLDGS INC NEW
 PRESS RELEASE

ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COV...

ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program Brings total awards from BARDA to $110 million for development of broad SARS-CoV-2 and Influenza multispecifics, with potential funding of up to $205 million if all options are executedDevelopment work is based on ModeX proprietary MSTAR technology that incorporates multiple antibody binding sites into a single molecule WESTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ: OPK) company, announces ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: October 5, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: October 4, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: September 28, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: September 24, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

OPKO Health’s ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Ch...

OPKO Health’s ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development WESTON, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ: OPK) company, today announced the appointment of Giovanni Abbadessa, M.D., Ph.D. as Chief Medical Officer, a newly created position. Dr. Abbadessa has over two decades of experience in drug development, including most recently as Vice President at Sanofi, where he provided executive leadership for advancing oncology assets. “Dr. Abbadessa’s deep ...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

AMREP Reports First Quarter Fiscal 2025 Results

AMREP Reports First Quarter Fiscal 2025 Results HAVERTOWN, Pa., Sept. 13, 2024 (GLOBE NEWSWIRE) -- AMREP Corporation (NYSE:AXR) today reported net income of $4,064,000, or $0.76 per diluted share, for its 2025 fiscal first quarter ended July 31, 2024 compared to net income of $1,346,000, or $0.25 per diluted share, for the same period of the prior year. Revenues were $19,091,000 for the first quarter of 2025 and $10,289,000 for the first quarter of 2024. More information about the Company’s financial performance may be found in AMREP Corporation’s financial statements on Form 10-Q whic...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: August 31, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch